| Abstract | Vascular dementia (VaD), like Alzheimer's disease (AD), is associated with cholinergic deficits. Rivastigmine provides sustained, brain-selective inhibition of acetylcholinesterase and butyrylcholinesterase. Preliminary data suggest that rivastigmine may provide significant benefits in patients with AD and cerebrovascular disease (mixed dementia), and in patients with VaD. Open-label rivastigmine treatment has been associated with improved cognitive and functional abilities, behavioral symptoms, and reduced caregiver stress in a small pilot study in these patients. Larger, prospective, double-blind studies of rivastigmine in patients with VaD are under way. These studies will confirm whether rivastigmine is an efficacious treatment option for a range of patients for whom, until now, there have been few symptomatic therapies. |
| Authors | Shoona Vincent, Roger Lane
(Affiliation: Novartis Pharmaceuticals, Surrey, UK.)
|
| Journal | International psychogeriatrics / IPA
(Int Psychogeriatr)
Vol. 15 Suppl 1
Pg. 201-5
( 2003)
ISSN: 1041-6102 United States |
| PMID | 16191241
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
| Chemical References |
- Cholinesterase Inhibitors
- Phenylcarbamates
- rivastigmine
- Butyrylcholinesterase
- Acetylcholinesterase
|
| Topics |
- Acetylcholinesterase
(metabolism)
- Activities of Daily Living
- Aged
- Alzheimer Disease
(diagnosis, drug therapy)
- Butyrylcholinesterase
(metabolism)
- Cholinesterase Inhibitors
(administration & dosage, pharmacology, therapeutic use)
- Cognition Disorders
(diagnosis)
- Dementia, Vascular
(diagnosis, drug therapy)
- Double-Blind Method
- Drug Administration Schedule
- Humans
- Neuropsychological Tests
- Phenylcarbamates
(administration & dosage, pharmacology, therapeutic use)
- Pilot Projects
- Severity of Illness Index
|
